{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-26-000041","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.294312+00:00","generated_at":"2026-05-14T23:52:00.774298+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Travere Q1 net product sales up 64% to $124.5M; FILSPARI approved for FSGS","bullets":["FILSPARI net sales $105.2M (+88% YoY); 993 new PSFs in IgAN during Q1.","FDA approved FILSPARI for FSGS on April 13; first patients treated within a week.","Net loss $37.1M ($0.40/sh) vs $41.2M ($0.47/sh); non-GAAP net income $4.1M ($0.05/sh).","Phase 3 HARMONY of pegtibatinase restarted; first new patient dosed; topline data due 2H 2027.","Cash & equivalents $264.7M as of March 31; $25M milestone from Mirum received in April."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-26-000041","json":"https://secwatch.observer/filing/0001438533-26-000041.json","markdown":"https://secwatch.observer/filing/0001438533-26-000041.md","text":"https://secwatch.observer/filing/0001438533-26-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/0001438533-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/tvtx-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:52:00.774298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec7f9dcceb2aefd312e3fdf4f06e5017b18f05d6","claim":"Travere Therapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $124.5 million, net income Net loss for the first quarter of 2026 was $37.1 million, or $0.40 per basic share, EPS $0.40 per basic share.","evidence_excerpt":"supporting a compelling long-term trajectory for the Company.” Financial Results for the Quarter Ended March 31, 2026 U.S. net product sales for the first quarter of 2026 were $124.5 million, compared to $75.9 million for the same period in 2025. The increase is attributable to growth in sales of FILSPARI. Research and development (R&D) expenses for the first quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/0001438533-26-000041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$124.5 million"},{"label":"Net income","value":"Net loss for the first quarter of 2026 was $37.1 million, or $0.40 per basic share"},{"label":"EPS","value":"$0.40 per basic share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}